Servier Announces FDA Approval of Tibsovo (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)

Tibsovo is the first and only approved targeted therapy for R/R MDS patients with a susceptible IDH1 mutation Fifth approved indication for Tibsovo solidifies Servier ' s leadership in mutant IDH inhibition  BOSTON, Oct. 24, 2023 /PRNewswire/...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news